It appears you're asking for insights into enGene Holdings Inc. (NasdaqCM: ENGN). As a quantitative analyst, I can provide a data-driven overview of the company's current standing based on Fintel's comprehensive data.
Here's a snapshot of ENGN:
- Company Overview: enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing gene therapies, particularly for oncology. A key focus is their LEGEND trial.1
- Financial Health: As of July 31, 2025, enGene reported $224.9 million in cash, cash equivalents, and marketable securities, which the company anticipates will fund operations into 2027. This follows $272.8 million as of January 31, 2025. The company reported a net loss of $24.6 million, or $0.48 per share, for the first quarter of 2025.2
- Market Valuation: ENGN currently has a market capitalization of $199.18 million, with a share price of $3.90 as of August 6, 2025. The stock has an EPS (TTM) of -1.56 and a Price/Book ratio of 0.88.3
- Institutional Ownership: Institutional investors hold a significant portion of ENGN, with 44 institutions owning 41.10 million shares, representing 80.43% of shares outstanding. However, there was a slight decrease of 1.29% in institutional shares long during the most recent quarter.4
- Short Interest: Short interest in ENGN is notably low, with only 23,363 shares shorted, equating to 0.09% of the float. The Days to Cover ratio is also very low at 0.09 days, suggesting minimal short squeeze potential.5
- Analyst Sentiment: Analyst sentiment appears largely positive, with an average one-year price target of $21.98, ranging from $7.07 to $31.50. As of August 1, 2025, ratings include 6 Strong Buys, 9 Buys, and 2 Holds. Recent analyst activity includes Piper Sandler initiating coverage with an Overweight rating in February 2025, while UBS downgraded the stock from Buy to Neutral around the same time.3
- Upcoming Milestones: The company has several critical milestones ahead, including updated preliminary data from the LEGEND trial's pivotal cohort in Q4 2025 and a planned Biologics License Application (BLA) filing in the second half of 2026.1
These data points suggest that while the company is pre-revenue and operating at a loss, it has a substantial cash runway and significant institutional backing, alongside positive analyst outlooks tied to its clinical pipeline.
